The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Until today this year the stock’s price performance recorded an increase of 2.38%. However, over the last six months, the performance has been stronger by -63.44%. The price of MRNA increased 2.26% over the last 30 days. And in the last five days, it has surged by 6.08%.
Moderna Inc saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $170.47 on 05/24/24, while the lowest price for the same duration was marked at $35.80 on 11/15/24.
52-week price history of MRNA Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Moderna Inc’s current trading price is -75.03% away from its 52-week high, while its distance from the 52-week low is 18.91%. The stock’s price range during this period has varied between$35.80 and $170.47. The Moderna Inc’s shares, which operate in the Healthcare, saw a trading volume of around 8.54 million for the day, a figure considerably higher than their average daily volume of 7.61 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Moderna Inc (MRNA) has experienced a quarterly decline of -29.29% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 16.45B and boasts a workforce of 5600 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 56.60, with a change in price of -40.33. Similarly, Moderna Inc recorded 6,740,345 in trading volume during the last 100 days, posting a change of -48.65%.
MRNA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for MRNA stands at 0.11. Similarly, the long-term debt-to-equity ratio is also 0.11.
MRNA Stock Stochastic Average
Moderna Inc’s raw stochastic average for the past 50 days is presently 30.93%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 51.44%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 48.23% and 45.36%, respectively.
